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Visceral leishmaniasis (VL) is the most severe form of leishmaniasis and is responsible for most Leishmania-associated deaths. VL
represents a serious public health problem that aﬀects many countries. The immune response in leishmaniasis is very complex
and is poorly understood. The Th1 versus Th2 paradigm does not appear to be so clear in visceral leishmaniasis, suggesting that
other immunosuppressive or immune-evasion mechanisms contribute to the pathogenesis of VL. It has been demonstrated that
generation of adenosine, a potent endogenous immunosuppressant, by extracellular enzymes capable to hydrolyze adenosine tri-
nucleotide (ATP) at the site of infection, can lead to immune impairment and contribute to leishmaniasis progression. In this
regard, this paper discusses the unique features in VL immunopathogenesis, including a possible role for ectonucleotidases in
leishmaniasis.
1.Introduction
Parasites that belong to the genus Leishmania are among
the most diverse human pathogens, both in terms of
geographical distribution and in the variety of infection-
induced clinical manifestations they generate. Of the 88
countries aﬀected by leishmaniasis, 72 are classiﬁed as
developing countries, including 13 of the least developed
countries. Despite the widespread distribution of leish-
maniasis, 90% of VL cases occur in just ﬁve countries:
Bangladesh, India, Nepal, Sudan, and Brazil [1]. Leishmania
are obligate intracellular protozoan parasites transmitted by
phlebotomine sand ﬂies. Flagellated promastigotes injected
by sand ﬂy bites replicate as intracellular amastigote stages
inside mononuclear phagocytic cells of mammalian hosts
[2, 3]. The epidemiology of leishmaniasis is diverse, with
20 Leishmania species that are pathogenic in humans and
30 sand ﬂy species that have been identiﬁed as vectors
[1]. This range of species variability culminates in diﬀerent
symptomatology and clinical manifestations that can be
classiﬁed into two broad disease presentations: cutaneous
leishmaniasis and VL [4].
Visceral leishmaniasis (VL) is caused by Leishmania
donovani (L. donovani) in the Indian subcontinent, Asia, and
Africa and by Leishmania infantum (L. infantum)o rLeish-
mania chagasi (L. chagasi) in the Mediterranean region,
southwest and central Asia, and South America; however,
other species, such as Leishmania amazonensis (L. ama-
zonensis) in South America, are occasionally viscerotropic
[5, 6]. VL is the most severe form of leishmaniasis and is
responsible for most deaths caused by leishmaniasis. The
disease commonly aﬀects the liver, spleen, and lymph nodes.
The pathophysiology of the disease is characterized by the
onset of symptoms of a persistent systemic infection, includ-
ing loss of appetite, weight loss, intermittent fever, fatigue,
and exhaustion. The incubation period usually ranges from
two to six months. Parasite dissemination occurs via the
vascular, lymphatic, and mononuclear phagocyte systems2 Journal of Tropical Medicine
andresultsinbonemarrowinﬁltration,hepatosplenomegaly,
and lymphadenopathy [7, 8].
In VL, the immune response is closely related to disease
progression and the development of clinical manifestations.
The syndromes and causative mediators are typical of
a slowly developing systemic inﬂammatory response syn-
drome with multiorgan failure. The absence of parasite
actions or products that would harm the host cells or tissues
is a further indication that the systemic pathogenicity of VL
is dependent on the host response [9].
2. Immune Response in Visceral Leishmaniasis:
The Th1 versusTh2 Paradigm
Cytokine production and the subsequent stimulation or
inactivation of certain immune cells in the early stages of an
infectionessentiallydeterminesthetypeofimmuneresponse
[10]. The complexity of the immunological events triggered
during active VL and the relevance of the segregation of
human immune responses during VL into type 1 and type
2 still remain unclear. Several studies have identiﬁed that
the major immunologic dysfunction observed in VL is the
inability of T cells to produce IL-2 and IFN-γ upon stimula-
tion with Leishmania antigens and to activate macrophages
and kill Leishmania parasites. Analysis of Th1 and Th2
cell-associated cytokines in peripheral blood samples from
patients with L. donovani-induced VL showed reduced IFN-
γ levels and increased IL-4 levels in comparison to healthy
patients in the control group [11].
Recent data have challenged the simplicity of Th1 versus
Th2 model and revealed further complexities in cytokine
regulation and the mechanisms of acquired resistance and
immune escape [3]. For some cases of VL, it appears that the
immune response is a mixed Th1 and Th2 type. In patients
with VL, although the production of type 1 cytokines
was not depressed, cells appeared to be unresponsive to
stimulation with type 1 cytokines [10]. Increased production
ofmultiplecytokinesandchemokinesinVLpatientswasalso
observed; the response was predominately proinﬂammatory,
as indicated by the elevated plasma levels of IL-1, IL-6, IL-8,
IL-12, IL-15, IFN-γ-inducible protein-10 (IP-10), monokine
induced by IFN-γ (MIG), IFN-γ, and tumor necrosis
factor (TNF)-α [2, 12]. Gene expression analysis in an in
vitro model, using human monocyte-derived macrophages
(MDMs) challenged with L. chagasi promastigotes that were
subsequently cocultured with or without Leishmania-na¨ ıve
autologous T-cells, found that the initial encounter between
L.chagasiandcellsoftheinnateandadaptiveimmunesystem
primarily stimulated type 1 immune cytokine responses.
Type 1 cytokine responses were produced despite a lack
of classical macrophage activation, suggesting that the local
microenvironment at the site of parasite inoculation may
determine the initial course of T-cell diﬀerentiation [13].
Investigations into the mechanisms underlying the
immunosuppression observed during acute VL have demon-
strated defective antigen-speciﬁc proliferation and IFN-γ
responses [14], which suggest that the parasites suppress
macrophage microbicidal responses, and IFN-γ signaling
pathways [15] at the earliest stages of infection. Also
supporting the absence of a clear Th1 versus Th2 dichotomy
in VL is the observation that inhibition of Th1 cytokines in a
murine model of L. chagasi-induced VL results in parasite
clearance independent of Th2 cytokines [16]. Studies, not
only in mice, but also in humans, suggested that cure
was independent of the diﬀerential production of Th1
and Th2 cytokines, and both IFN-γ and IL-4 producing
T cells have been isolated from asymptomatic and cured
patients [17]. These immunosuppressive mechanisms could
diﬀer depending upon etiologic agent, T-cell subpopulation
predominance at site of infection, stage of infection, and
target organ. Such mechanisms could be even more complex
because the course Leishmania infection may vary widely
depending on the species and strain of parasite.
3. ImmunomodulatoryEffectsofAdenosineand
Adenosine Triphosphate (ATP) Nucleotidases
In studying the complexity of immune system regulation,
especially at the site of injury, several groups have recently
begun to demonstrate a possible role for the nucleoside
adenosine and adenosine nucleotidases in regulating Leish-
mania-speciﬁc immune responses. It was proposed that
ecto-ATPdiphosphohydrolasesandectonucleotidases,which
are membrane-associated enzymes with their catalytic sites
turnedextracellular,wouldacttodephosphorylateadenosine
nucleotides into free adenosine [18, 19]. Before discussing
the role of ectonucleotidases in leishmaniasis, concepts
and comments regarding the immunomodulatory roles of
adenosine nucleotides and nucleosides must be stressed.
Extracellular nucleotides are involved in a variety of
physiological functions by participating in extracellular
signaling through the activation of cell surface metabotropic
purinergic (G protein coupled) and ionotropic (ion channel
coupled) receptors. The major classes of purinergic receptors
include the type P2 receptors (P2X-P2Y) and ionotropic
and metabotropic receptors [20–22]. The activation of
these receptors by ATP leads to proinﬂammatory eﬀects by
initiating a response characterized by the secretion of IFN-γ,
IL-12, and TNF-α [23].
Duringacuteinﬂammation,theATPreleasedbytheleak-
ageofcellularcontentscanbesequentiallydephosphorylated
by the action of ectonucleotidases, causing the concentration
of extracellular adenosine to increase markedly [22, 24].
Adenosineexertsdistincteﬀectsontheimmunesystemcom-
pared to ATP. The immunosuppressive actions of adenosine
aretriggeredbyactivationoffourreceptorsubtypes(A1,A 2A,
A2B,a n dA 3) belonging to the family of purinergic receptors
known as P1 or A. These receptor subtypes are members of a
superfamily of receptors composed of seven transmembrane
regions that are coupled to G proteins [22, 25] and expressed
in neutrophils, macrophages, dendritic cells [26], and T cells
[27]. These four adenosine receptor subtypes are expressed
concomitantly in various immune cells [28, 29].
Purinergic signaling depends on several factors, includ-
ing receptor expression, receptor sensitivity, and the levels of
extracellular nucleotides and nucleosides. The concentration
of extracellular adenosine can determine the activation
of a given receptor due to the diﬀerence in A receptorsJournal of Tropical Medicine 3
aﬃnity[28].Inphysiologicaladenosineconcentrations(0.2–
0.5μM), the A1 and A3 receptors are preferentially activated,
while at higher adenosine concentrations (16,2–64,1μM),
such as those seen in inﬂammation, A2B receptors exert their
eﬀects [30].
Activation of A2A and A2B receptors leads to increased
levels of intracellular cAMP by activating adenylyl cyclase,
which inhibits immune cell function [31]. This regulatory
eﬀect is caused mainly by inhibiting the production of IFN-
γ, IL-12, and TNF-α coupled with an increased production
of IL-10 [32] as summarized in Figure 1. Inhibition of
monocyte maturation and the suppression of macrophage
phagocytic function are also related to the activation of A2
receptors [33]. The signaling pathway that couples A2A and
A2B adenosine receptors with G proteins is balanced by the
signaling that results from the association of A1 and A3
receptors with Gi protein, which inhibits adenylyl cyclase.
Adenylyl cyclase inhibition then leads to decreased levels of
cAMP,whichlimitstheprematureinhibitionofimmunecells
by A2 receptors [34].
4. Adenosine andthe Establishment of
Leishmania Infection: The Possible Role of
Ectonucleotidases inImmuneImpairment
Ectonucleotidases are glycoprotein enzymes present in the
plasma membrane with their catalytic sites facing extracellu-
larly [18, 19], which are capable of hydrolyzing extracellular
nucleotides. Fundamentally important in maintaining the
homeostasis of extracellular nucleotides, these enzymes are
also regulatory (termination of signaling events triggered by
ATP) and metabolic (generation of nutrients) in function
[35]. The hydrolysis of extracellular nucleotides occurs in
a sequential manner by the action of ecto-ATPase, ecto-
ADPase, ecto-ATPDase, and ecto-5-nucleotidase [36]. The
classiﬁcation of ectonucleotidases in diﬀerent families takes
into account kinetic aspects such as enzyme speciﬁcity and
substrate aﬃnity and molecular aspects of protein structure
[37].
Since Gottlieb and Dwyer [38] provided information
in 1981 about the biochemistry of surface membranes of
Leishmania, a large number of authors have observed
nucleotidases located on the outer surface of the plasma
membrane of the parasite. For example, ecto-ATPases,
ecto-5-nucleotidase, and ecto-3-nucleotidase have all been
described in Leishmania sp. [18, 19, 39, 40].
In Leishmania parasites, it was proposed that an increase
in ectonucleotidase activity would increase the produc-
tion of adenosine, which would consequently aid in the
establishment of infection through its immunosuppressive
mechanisms. Infective L. amazonensis promastigotes exhibit
higher ATPase activity compared to nonvirulent promastig-
otes [39]. Furthermore, amastigotes, which are responsible
for maintenance of leishmaniasis in the vertebrate host, are
capable of hydrolyzing ATP at higher rates than promastig-
otes [40]. L. amazonensis strains that possess higher ectonu-
c l e o t i d a s ea c t i v i t ya r em o r ee ﬀective in establishing infection
in murine models [41]. Comparison of ectonucleotidase
activities between L. amazonensis, Leishmania braziliensis (L.
braziliensis), and L. major showed that the more virulent
parasite causing nonhealing lesions in C57BL/6 mice (e.g.,
L. amazonensis) hydrolyzes higher amounts of ATP, ADP,
and 5AMP [42]. Furthermore, adenosine treatment at the
time of L. braziliensis inoculation delays lesion resolution
and induces increased parasite burdens. Consistent with this,
inhibition of adenosine receptor A2B led to decreased lesion
size and lower parasite burden [43]. In clinical practice,
results that are consistent with the idea that ecto-ATPase
activity is involved in virulence were also observed, whereby
L. amazonensis strain isolated from a human case of VL
possesshigherecto-ATPaseactivitythanstrainsisolatedfrom
CL cases [44].
In addition to these ectonucleotidases, Leishmania par-
asites also express a bifunctional enzyme called 3-nucle-
otidase/nuclease (3NT/NU) in the plasma membrane with
a high capacity to hydrolyze 3ribonucleotides and nucleic
acids [43, 45]. Although ﬁrst identiﬁed in L. donovani [43,
45], it was later found in L. chagasi [46], L. major [47],
L. mexicana [48], and L. amazonensis. Although the 3-
nucleotidase enzyme is found solely in some trypanoso-
matids, 3-nucleotides are available through nucleic acid
hydrolysis in several mammalian tissues [49], especially the
spleen,anorgancommonlytargetedbyLeishmaniaparasites.
Recently, our group has characterized the 3-nucleotidase
activity of L. chagasi and demonstrated that such activity
could be related to aspects of parasite virulence [46].
Interestingly,theviscerotropicL.chagasiandL.donovanihad
higher 3-nucleotidase activity compared to the New World
and Old World dermatotropic species (e.g., L. amazonensis,
L.major,L. tropica,and L.braziliensis).L.chagasimetacyclics
(infective promastigote stage) had higher 3-nucleotidase
activity compared to L. chagasi nonmetacyclics (noninfective
promastigote stage) [46]. Similar results were also observed
withL.amazonensis,whereinfectivepromastigotespossessed
twofold higher 3-nucleotidase activity compared to nonvir-
ulent promastigotes [50].
In addition to the role of ectonucleotidase in the
establishment of Leishmania infection by ectonucleotidases,
some interesting data have further demonstrated that high
expression/activity of such enzymes on immune cells con-
tributes to immune imbalance. CD4+CD25+ regulatory T
cells (Tregs) from mutant mice deﬁcient in CD39 have
impaired regulatory function manifesting as a 50% decrease
in the ability of CD39-null Tregs to modulate eﬀector T-
cell function in vitro and in vivo. These results indicate
that CD39 expressed by Treg is the major and rate-limiting
ectonucleotidase responsible for the generation of adenosine
and suggest that a putative CD39/CD73-adenosinergic axis
may contribute to the immunoregulatory function of Treg
[51, 52].
In L. infantum-infected BALB/c mice, Tregs are present.
The high levels of Foxp3 gene expression and surface expres-
sion of Eb7 integrin (CD103) suggest a predisposition for
Treg retention within sites of L. infantum infection, as is the
case of the spleen and draining lymph nodes, consequently
inﬂuencing localimmune response[53].Itwasattributingto
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Figure 1: Partial reactions catalyzed by ecto-nucleoidases: (1) ecto-ATPase, ectonucleoside triphosphate diphosphohydrolase; (2) ecto-5-
nucleotidase; (3) ecto-3-nucleotidase. The sequential hydrolysis of extracellular ATP by Leishmania ectonucleotidases triggers the host
inﬂammatory and immune response following P2 receptor activation by extracellular ATP (blue square) and P1 (A2) receptors activation by
extracellular adenosine nucleoside (yellow square). ADO: Adenosine.
immune suppression because in those cells, CD39 and CD73
are overexpressed. Inhibitors of ectonucleotidase activities
and antagonists of the A2A receptor blocked Treg-mediated
immunosuppression [54]. Consistent with this view, it was
demonstrated that patients with VL possess high levels of
adenosine, which was related to ectonucleotidase activities
and disease progression [55].
This paper about the immune modulatory eﬀects of
adenosine and the production of such nucleoside by par-
asite and immune cells provide new perspectives for the
understanding of the complex immune response in leishma-
niasis. Further studies are needed, especially using visceral
leishmaniasis models, to clearly delineate the role of ectonu-
cleotidases in the establishment of infection and Leishmania-
induced immunomodulation.
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